1. FLIP: Molecular switch between apoptosis and necroptosis
    JingJing Gong et al, 2014, Molecular Carcinogenesis CrossRef
  2. The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
    Daniel E Johnson, 2015, Endocrine-Related Cancer CrossRef
  3. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
    G.R. Tundo et al, 2020, Pharmacology & Therapeutics CrossRef
  4. MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer
    Weijiang Zhang et al, 2017, Gene CrossRef
  5. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism
    J Bullenkamp et al, 2014, Cell Death & Disease CrossRef
  6. Co-expression analysis reveals key gene modules and pathways of oral squamous cell carcinoma
    Xiao Li et al, 2018, Cancer Biomarkers CrossRef
  7. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells
    Eun-Sil Sung et al, 2012, Experimental Cell Research CrossRef
  8. TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis
    Syam Prakash Somasekharan et al, 2013, Apoptosis CrossRef
  9. Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches
    Jason I. Kass et al, 2014, Resistance to Proteasome Inhibitors in Cancer CrossRef